PARP inhibitor resistance: the underlying mechanisms and clinical implications

Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi targeting poly (ADP-ribose) polymerase (PARP) have been approved for ovarian cancer and breast cancer indications. However...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, He, Liu, Zhao-Yi, Wu, Nayiyuan, Chen, Yong-Chang, Cheng, Quan, Wang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305609/
https://www.ncbi.nlm.nih.gov/pubmed/32563252
http://dx.doi.org/10.1186/s12943-020-01227-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305609/
https://www.ncbi.nlm.nih.gov/pubmed/32563252
http://dx.doi.org/10.1186/s12943-020-01227-0

Ejemplares similares